Shinji Nakamura

This inventor holds 66 USPTO granted patents and 6 published patent applications and 16 EPO patents, primarily in Heterocyclic Compounds (CPC class C07D). Top assignees: Matsushita Electric Industrial Co., Ltd., Takeda Pharmaceutical Company Limited, Matsushita Electronics Corporation. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinji Nakamura. Retrieved from https://idiyas.com/inventor/shinji-nakamura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 66 (Patent Applications = 6)

% Patents Active = 59.1

EPO Patents = 16 (Patent Applications = 9)

Average Co-Inventor Count = 5.1

ph-index = 14

Forward Citations = 504(Granted Patents)

Forward Citations (Not Self Cited) = 465(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Matsudo, JP (1998 - 1999)
Ikoma, JP (1998 - 2000)
Katano, JP (2002 - 2006)
Osaka, JP (2000 - 2010)
Fujisawa, JP (2020 - 2023)
Kanagawa, JP (2005 - 2024)

Company Filing History:

31 out of 27,375

Matsushita Electric Industrial Co., Ltd.

patents

20 out of 1,226

Takeda Pharmaceutical Company Limited

patents

5 out of 655

Matsushita Electronics Corporation

Panasonic Corporation

patents

6. 1 out of 92,994

Canon Kabushiki Kaisha

patents

7. 1 out of 191

Japan Display West Inc.

patents

8. 1 out of 28

Matushita Electric Industrial Co., Ltd.

patents

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

GPR139 Antagonists

AMPA Receptor Function

Liquid Crystal Displays

Circuit Board Manufacturing

Pyrido-Pyrimidines

Phosphodiesterase Inhibitors

Transreflective LCD

Color Adjusting Windows

Nitrogenated Compounds

Sulfonamide Derivatives

Printed Wiring Boards

66 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630534 - 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression (2026-05-19),

2. 12590086 - 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression (2026-03-31),

3. 11939327 - Heterocyclic compounds (2024-03-26),

4. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

5. 11447488 - Heterocyclic compounds (2022-09-20),

6. 11407748 - Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function (2022-08-09),

7. 11290051 - Motor control apparatus and control method of the same (2022-03-29),

8. 11279713 - Heterocyclic compound and use thereof (2022-03-22),

9. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

10. 10654874 - Heterocyclic compound and use thereof (2020-05-19),

11. 10017508 - Nitrogenated heterocyclic compound (2018-07-10),

12. 9884875 - Heterocyclic compound and use thereof (2018-02-06),

13. 9527841 - Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors (2016-12-27),

14. 9527807 - Sulfonamide derivative and use thereof (2016-12-27),

15. 9499568 - Heterocyclic compound and use thereof (2016-11-22),

Title: **Shinji Nakamura: A Pioneer in Heterocyclic Compound Innovations**

Introduction

Shinji Nakamura is a prominent inventor based in Osaka, Japan, renowned for his significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 64 patents, Nakamura specializes in the development of heterocyclic compounds that have potential therapeutic applications for various neurological and psychological conditions.

Latest Patents

Nakamura's latest patents include groundbreaking inventions focused on heterocyclic compounds. One noteworthy invention aims to provide a heterocyclic compound with an AMPA receptor potentiator effect, which shows promise as a treatment for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), and more. This compound is characterized by specific formulas detailed in his patent specifications. Another significant patent revolves around a heterocyclic compound that exhibits an antagonistic action on an NMDA receptor comprising the NR2B subunit. This invention is anticipated to offer a therapeutic avenue for major depression, bipolar disorder, migraine, pain, and the behavioral and psychological symptoms associated with dementia, again specified through detailed compound representations in the patent documentation.

Career Highlights

Throughout his impressive career, Nakamura has worked with several leading companies, including Matsushita Electric Industrial Co., Ltd. and Takeda Pharmaceutical Company Limited. His time at these organizations has allowed him to hone his skills and contribute significantly to the advancement of pharmaceutical research and development.

Collaborations

In his pursuit of innovation, Nakamura has collaborated with notable individuals in the field, such as Toshihiro Nishii and Masaaki Yuri. These partnerships have not only facilitated the exchange of ideas but have also inspired a collaborative environment aimed at addressing complex health challenges through inventive solutions.

Conclusion

Shinji Nakamura stands out as a dedicated inventor who continues to make remarkable strides in the field of pharmaceutical innovations. His contributions through various patents exemplify the importance of heterocyclic compounds in addressing critical health issues, reaffirming the role of invention in advancing medical science. As his journey unfolds, Nakamura's work is poised to create lasting impacts on therapeutic practices worldwide.

Profile summary based on public USPTO records.